Cannabinoid-Ligand Platinum Complexes for Dual Tumor Activity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current platinum-based anti-neoplastic agents lack additional therapeutic benefits beyond DNA alkylation, such as anti-tumor activity and inhibition of tumor progression.
Innovation Solution
Incorporation of a cannabinoid ligand as a leaving or axial ligand in platinum complexes, which is released upon entry into cells to provide additional therapeutic benefits.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a cannabinoid ligand is incorporated into platinum complexes, then anti-tumor activity and inhibition of tumor progression are enhanced, but the complexity of the drug structure increases
Solution Approach 1:
The patent combines a cannabinoid ligand with a platinum complex to create a hybrid molecule that integrates the DNA-alkylating capability of platinum with the anti-tumor and tumor progression-inhibiting properties of cannabinoids. This merging allows a single agent to deliver multiple therapeutic effects simultaneously, resolving the contradiction by enhancing reliability through functional integration while managing complexity through rational molecular design
Solution Approach 2:
The cannabinoid-platinum conjugate is designed to perform multiple functions: the platinum component provides DNA alkylation while the cannabinoid component contributes anti-tumor activity and inhibition of tumor progression. This multi-functionality allows the single drug molecule to address multiple aspects of cancer pathology, thereby enhancing overall therapeutic reliability without requiring multiple separate medications
2Reliability
If a cannabinoid ligand is incorporated into platinum complexes, then additional therapeutic benefits are provided, but the manufacturing complexity increases
Solution Approach 1:
The synthesis approach divides the creation of the cannabinoid-platinum conjugate into distinct stages: first preparing the cannabinoid precursor with appropriate functional groups, then coordinating the platinum complex to the cannabinoid scaffold. This segmentation of the manufacturing process allows each component to be optimized independently while simplifying quality control and scale-up procedures
Solution Approach 2:
The patent employs intermediary compounds during synthesis, such as cannabinoid derivatives with pre-installed coordinating groups that facilitate controlled attachment of the platinum complex. These intermediaries serve as bridging molecules that enable modular assembly, thereby reducing overall manufacturing complexity while preserving the full therapeutic benefits of the final conjugate
Data Source
AI summary
This disclosure provides platinum complex anti-neoplastic agents that comprise at least one cannabinoid ligand as either a leaving ligand or an axial ligand. After the agent enters the cell, the cannabinoid ligand is released as a cannabinoid, where the cannabinoid can then provide additional therapeutic benefits.